Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein
Open Access
- 23 November 2020
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 94 (24)
- https://doi.org/10.1128/jvi.01176-20
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory illness and has a high mortality of ∼34%. However, since its discovery in 2012, an effective vaccine has not been developed for it. To develop a vaccine against multiple strains of MERS-CoV, we targeted spike glycoprotein (S) using prime-boost vaccination with DNA and insect cell-expressed recombinant proteins for the receptor-binding domain (RBD), S1, S2, SΔTM, or SΔER. Our S subunits were generated using an S sequence derived from the MERS-CoV EMC/2012 strain. We examined humoral and cellular immune responses of various combinations with DNA plasmids and recombinant proteins in mice. Mouse sera immunized with SΔER DNA priming/SΔTM protein boosting showed cross-neutralization against 15 variants of S-pseudovirions and the wild-type KOR/KNIH/002 strain. In addition, these immunizations provided full protection against the KOR/KNIH/002 strain challenge in human DPP4 knock-in mice. These findings suggest that vaccination with the S subunits derived from one viral strain can provide cross-protection against variant MERS-CoV strains with mutations in S. DNA priming/protein boosting increased gamma interferon production, while protein-alone immunization did not. The RBD subunit alone was insufficient to induce neutralizing antibodies, suggesting the importance of structural conformation. In conclusion, heterologous DNA priming with protein boosting is an effective way to induce both neutralizing antibodies and cell-mediated immune responses for MERS-CoV vaccine development. This study suggests a strategy for selecting a suitable platform for developing vaccines against MERS-CoV or other emerging coronaviruses. IMPORTANCE Coronavirus is an RNA virus with a higher mutation rate than DNA viruses. Therefore, a mutation in S-protein, which mediates viral infection by binding to a human cellular receptor, is expected to cause difficulties in vaccine development. Given that DNA-protein vaccines promote stronger cell-mediated immune responses than protein-only vaccination, we immunized mice with various combinations of DNA priming and protein boosting using the S-subunit sequences of the MERS-CoV EMC/2012 strain. We demonstrated a cross-protective effect against wild-type KOR/KNIH/002, a strain with two mutations in the S amino acids, including one in its RBD. The vaccine also provided cross-neutralization against 15 different S-pseudotyped viruses. These suggested that a vaccine targeting one variant of S can provide cross-protection against multiple viral strains with mutations in S. The regimen of DNA priming/Protein boosting can be applied to the development of other coronavirus vaccines.Keywords
Funding Information
- Ministry of Health and Welfare (HI15C2971)
This publication has 36 references indexed in Scilit:
- Protein energy malnutrition alters mucosal IgA responses and reduces mucosal vaccine efficacy in miceImmunology Letters, 2017
- Mapping and Role of the CD8 + T Cell Response During Primary Zika Virus Infection in MiceCell Host & Microbe, 2017
- A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infectionVirology, 2016
- Variations in Spike Glycoprotein Gene of MERS-CoV, South Korea, 2015Emerging Infectious Diseases, 2016
- Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27Scientific Reports, 2015
- Dromedary Camels and the Transmission of Middle East Respiratory Syndrome Coronavirus (MERS-CoV)Transboundary and Emerging Diseases, 2015
- Evaluation of candidate vaccine approaches for MERS-CoVNature Communications, 2015
- A decade after SARS: strategies for controlling emerging coronavirusesNature Reviews Microbiology, 2013
- Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in HumansmBio, 2012
- Improved Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine Encoding Ag85 by Protein BoostingInfection and Immunity, 2001